Journal Article Review Epublish
PubMed: 40375314 DOI: 10.1186/s13287-025-04371-w
Mesenchymal stem/stromal cells as a therapeutic for sepsis: a review on where do we stand?
Stem Cell Res Ther 16(1):245
Authors: Courtney Premer, Joshua M Hare, Sarah Y Yuan, Jason W Wilson
Affiliations
- Department of Emergency Medicine, McGaw Medical Center of Northwestern University, 211 E Ontario Street, Suite 200, Chicago, IL, 60611, USA.
- Department of Medicine, Division of Cardiovascular Medicine, Interdisciplinary Stem Cell Institute (ISCI), University of Miami, Miami, FL, USA.
- Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
- Department of Emergency Medicine, Morsani College of Medicine, Tampa General Hospital, University of South Florida, Tampa, FL, USA.
Abstract
Sepsis is one of the leading causes of morbidity and mortality in the United States and Worldwide despite advances in quick recognition and early antibiotics, fluids, and vasopressors. Mesenchymal stem/stromal cells (MSCs) have gained attention as a biologic therapy given their unique anti-inflammatory, immunomodulatory, and anti-bacterial characteristics. MSCs have had success in treating a range of diseases, however limited clinical trials exist specifically for MSC use in sepsis. This article reviews the properties of MSCs that make them favorable for treating sepsis, as well as the current state of clinical trials. All clinical trials presented here demonstrated MSC safety, with a mixture of efficacy results and a heterogeneity of trial methods. Ultimately, MSCs are a promising novel therapeutic for sepsis, however a consensus in cell source, dosage, preparation, and delivery needs to be further investigated for MSCs to transition from bench to bedside and become a true therapeutic for sepsis.
MeSH
Cells, Microscopy, Electron, Scanning Transmission, Stem Cells, Sepsis, Therapeutics, Stromal Cells